Imunon Reports Enrollment Above Expectations in Phase 3 Trial of IMNN-001 to Treat Ovarian Cancer

Phase 3IMNN-001Positive

AI Analysis

Summary

Imunon reported that enrollment in its Phase 3 trial of IMNN-001 for ovarian cancer exceeded expectations. The enrollment milestone demonstrates progress in the clinical development program.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Enrollment above expectations

Importance:6/10

Sentiment:

0.60

Phase 3 TrialOvarian CancerEnrollmentClinical Development

Related Companies

$IMNN

Read the original article

Published by yahoo_finance on July 30, 2026 2:11 PM

Read Original